Q-omics provides the consensus-scored MRPS18CP7 profile across patient tissues and cancer cell-line models. MRPS18CP7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MRPS18CP7 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, MRPS18CP7 RNA expression shows 5,317 significant pathway-activity associations, with the highest sampling consensus in OV. Together, these results highlight LIHC, COAD, and OV as cancer lineages where MRPS18CP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS18CP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS18CP7 survival associations across molecular data types. MRPS18CP7 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS18CP7 RNA expression–survival associations across cancer types. High MRPS18CP7 expression shows unfavorable associations in LIHC, LUAD and MESO, but favorable associations in CESC, KIRP and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for MRPS18CP7 RNA expression.
This table summarizes MRPS18CP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MRPS18CP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS18CP7 shows lower tumor expression in KIRP and higher tumor expression in COAD, STAD and KIRC. The COAD box plot shows higher MRPS18CP7 RNA expression in tumor versus normal tissue (log2 FC = +0.243, t-test p = .006).
This table shows molecular features associated with MRPS18CP7 in patient tissues and cancer cell lines. In patient samples, MRPS18CP7 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
